WaferGen Bio-Systems (WGBS) Misses Q2 EPS by 8c; Trims FY16 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
WaferGen Bio-systems Reports Results for Second Quarter 2016
August 9, 2016 4:02 PM EDTFREMONT, Calif., Aug. 9, 2016 /PRNewswire/ -- WaferGen Bio-systems, Inc. (NASDAQ: WGBS), a life sciences company focused on developing and commercializing technology platforms for genomic solutions, announced today its financial results for the second quarter ended June 30, 2016.
Key Recent Highlights
Announced in May 2016 the proposed merger with Takara Bio USA Holdings Inc. and certain of its affiliates, pursuant to which Takara would acquire the Company for a multiple of the Company's 2016 revenue, subject to certain... More